The global active pharmaceutical ingredients market was valued at US$ 168.9 Bn in the year 2018 and is expected to reach US$ 273.3 Bn by the year 2026, growing at a CAGR of 6.2% during the forecast period.
An active pharmaceutical ingredient is that part of a drug that is intended to provide pharmacological activity, i.e., biological activity, in the treatment or prevention of diseases, or is intended to affect the function or structure of the human body.
The major factors driving the growth of the active pharmaceutical ingredients market are the increasing prevalence of chronic diseases, increasing uptake of biopharmaceutical products, and the rising importance of generic drugs. However, the increasing penetration of counterfeit drugs and drug price control policies across the globe are expected to impede the growth of this market.
The active pharmaceutical ingredients market was earlier dominated by cardiovascular, anti-infective, pain management, and analgesic drugs. However, the market has been witnessing an increasing demand for complex and novel formulations for the treatment of cancer, metabolic disorders, and autoimmune diseases.
The global active pharmaceutical ingredients market report covers an in-depth analysis of the market including statistical and subjective data points, along with the key market drivers and opportunities & restraints that have positive or negative effects on the overall global market. An in-depth analysis of the regional and country level market at the various segment and sub-segment levels has been provided. The report comprises a competitive analysis of the key players functioning in the market and covers in-depth data related to the competitive landscape of the market and the recent strategies & product launches that will assist or affect the market in the near future.
Cardiovascular diseases are expected to hold the largest market share in the therapeutic application segment
The high prevalence of cardiovascular diseases is one of the major factors for the dominance of the cardiovascular application segment. According to the World Health Organization, cardiovascular diseases are the number one cause of death globally, with an estimated 17.9 million of CVD related deaths in 2016. This number is expected to reach 187 million by the year 2030. The estimated global cost of cardiovascular disease was around US$ 863 Bn in 2010 and is expected to reach US$ 1,044 Bn by the year 2030.
The key drugs classes for the treatment of cardiovascular diseases are blood pressure lowering drugs and cholesterol reducing drugs. Statins are the most important family of drugs that is expected to drive the growth of the cardiovascular disease segment.
The oncology therapeutic application is expected to grow at the highest rate during the forecast period. The International Agency for Research on Cancer estimates that the global incidence of cancer will reach 29.5 million by 2040, from 18.1 million in 2018. The increasing prevalence of cancer, coupled with the launch of new synthetic and biologic drugs for the treatment of cancer, is expected to drive the oncology application segment.
Biotech API segment is expected to grow at the highest CAGR during the forecast period
Based on the synthesis type, the active pharmaceutical ingredients market has been segmented into synthetic API and biotech API. The synthetic segment held the highest share in the base year. However, the biotech sub-segment is expected to grow at the highest CAGR during the forecast period. The high efficiency of biotech molecules, coupled with the increasing demand for biopharmaceuticals, is expected to drive the market for this segment. The biotech API segment is further divided into monoclonal antibodies, recombinant proteins, and others. The biotech API segment can be further divided into mammalian expression systems, yeast expression systems, microbial expression systems, and others, on the basis of the expression system.
North America is expected to dominate the market
In the base year 2018, North America dominated the market, followed by Europe. The major reasons behind the dominance of North America are the increasing prevalence of chronic diseases in the region and growing healthcare expenditure. Technological advancements in the manufacturing process of active pharmaceutical ingredients, increasing prevalence of cancer, and the rising demand for biologics are some other factors that are expected to drive the growth of the API market in North America.
However, Asia-Pacific is expected to grow at the highest CAGR during the forecast period. The majority of API manufacturers have presence in China or India. The region has advantages such as the availability of a cheap and talented labour pool. Additionally, the increasing prevalence of chronic diseases, rising incidence of cancer, and the increasing demand for quality healthcare in this region are also expected to augment the growth of the API market in the Asia-Pacific region.
Company Profiles and Competitive Intelligence:
The major players operating in the active pharmaceutical ingredients market are AbbVie Inc. (US), AstraZeneca Plc (UK), Boehringer Ingelheim (Germany), Bristol-Myers Squibb (US), Eli Lilly and Company (US), GlaxoSmithKline Plc. (UK), Merck & Co. Inc. (US), Novartis AG (Switzerland), Pfizer Inc. (US), and Teva pharmaceuticals (Israel), amongst others.
Pfizer Inc. is one of the leading players in the API market with a strong product portfolio and a strong brand image, which give it a competitive edge over the other players. In order to further strengthen its position in the market, the company has adopted both organic and inorganic strategies of growth such as partnerships, agreements, new product launches, and acquisitions, amongst others.
Teva pharmaceuticals is one the leaders in the API market, with over 370 quality APIs manufactured at its production facilities. The company has a strong R&D team of around 800 scientists and significant investments in R&D that have ensured a steady flow of API compounds.
Chapter 1 Preface
1.1 Report Description
1.1.1 Purpose of the Report
1.1.2 Target Audience
1.1.3 USP and Key Offerings
1.2 Research Scope
1.3 Research Methodology
1.3.1 Phase I – Secondary Research
1.3.2 Phase II – Primary Research
1.3.3 Phase III – Expert Panel Review
1.3.4 Approach Adopted
1.3.4.1 Top-Down Approach
1.3.4.2 Bottom-Up Approach
1.3.5 Assumptions
1.4 Market Segmentation Scope
Chapter 2 Executive Summary
2.1 Market Summary
2.1.1 Global Active Pharmaceutical Ingredients Market, 2016-2026, (US$ Mn)
2.1 Market Snapshot: Global Active Pharmaceutical Ingredients Market
2.2 Market Dynamics
2.3 Global Active Pharmaceutical Ingredients Market, by Segment, 2018
2.3.1 Global Active Pharmaceutical Ingredients Market, by Type, 2018 (US$ Mn)
2.3.2 Global Active Pharmaceutical Ingredients Market, by Type of Synthesis, 2018 (US$ Mn)
2.3.3 Global Active Pharmaceutical Ingredients Market, by Type of Manufacturer, 2018 (US$ Mn)
2.3.4 Global Active Pharmaceutical Ingredients Market, by Therapeutic Application, 2018 (US$ Mn)
2.3.5 Global Active Pharmaceutical Ingredients Market, by Region, 2018 (US$ Mn)
2.4 Premium Insights
2.4.1 Active Pharmaceutical Ingredients Market In Developed Vs. Developing Economies, 2018 vs 2026
2.4.2 Global Active Pharmaceutical Ingredients Market: Regional Life Cycle Analysis
Chapter 3 Market Dynamics
3.1 Market Overview
3.2 Market Drivers
3.2.1 Increasing prevalence chronic diseases
3.2.2 Increasing uptake of biopharmaceuticals
3.2.3 Technological advancements in API manufacturing
3.2.4 Increasing uptake of generics
3.3 Market Restraints
3.3.1 Increasing Penetration of Counterfeit drugs
3.3.2 Unfavourable drug price control policies
3.4 Market Opportunities
3.4.1 Increasing demand from emerging countries
3.4.2 Opportunity 2
3.5 Industry SWOT Analysis
Chapter 4 Global Active Pharmaceutical Ingredients Market, by Type
4.1 Market Overview, by Type
4.1.1 Global Active Pharmaceutical Ingredients Market, by Type, 2016-2026 (US$ Mn)
4.1.2 Incremental Opportunity, by Type, From 2018-2026
4.2 Innovative APIs
4.2.1 Global Active Pharmaceutical Ingredients Market, by Innovative APIs, 2016-2026, (US$ Mn)
4.3 Generic APIs
4.3.1 Global Active Pharmaceutical Ingredients Market, by Generic APIs, 2016-2026, (US$ Mn)
Chapter 5 Global Active Pharmaceutical Ingredients Market, by Type of Synthesis
5.1 Market Overview, by Type of Synthesis
5.1.1 Global Active Pharmaceutical Ingredients Market, by Type of Synthesis, 2016-2026 (US$ Mn)
5.1.2 Incremental Opportunity, by Type of Synthesis, From 2018-2026
5.2 Synthetic APIs
5.2.1 Global Active Pharmaceutical Ingredients Market, by Synthetic APIs, 2016-2026, (US$ Mn)
5.3 Biotech APIs
5.3.1 Global Active Pharmaceutical Ingredients Market, by Biotech APIs, 2016-2026, (US$ Mn)
5.4 Biotech API, by Type
5.4.1 Monoclonal Antibodies
5.4.2 Global Active Pharmaceutical Ingredients Market, by Monoclonal Antibodies, 2016-2026, (US$ Mn)
5.4.3 Recombinant Proteins
5.4.4 Global Active Pharmaceutical Ingredients Market, by Recombinant Proteins, 2016-2026, (US$ Mn)
5.4.5 Others
5.4.6 Global Active Pharmaceutical Ingredients Market, by Others, 2016-2026, (US$ Mn)
5.5 Biotech API, by Expression System
5.5.1 Mammalian Expression Systems
5.5.2 Global Active Pharmaceutical Ingredients Market, by Mammalian Expression Systems, 2016-2026, (US$ Mn)
5.5.3 Yeast Expression Systems
5.5.4 Global Active Pharmaceutical Ingredients Market, by Yeast Expression Systems, 2016-2026, (US$ Mn)
5.5.5 Microbial Expression Systems
5.5.6 Global Active Pharmaceutical Ingredients Market, by Microbial Expression Systems, 2016-2026, (US$ Mn)
5.5.7 Other Expression Systems
5.5.8 Global Active Pharmaceutical Ingredients Market, by Other Expression Systems, 2016-2026, (US$ Mn)
Chapter 6 Global Active Pharmaceutical Ingredients Market, by Type of Manufacturer
6.1 Market Overview, by Type of Manufacturer
6.1.1 Global Active Pharmaceutical Ingredients Market, by Type of Manufacturer, 2016-2026 (US$ Mn)
6.1.2 Incremental Opportunity, by Type of Manufacturer, From 2018-2026
6.2 Captive APIs
6.2.1 Global Active Pharmaceutical Ingredients Market, by Captive APIs, 2016-2026, (US$ Mn)
6.3 Merchant APIs
6.3.1 Global Active Pharmaceutical Ingredients Market, by Merchant APIs, 2016-2026, (US$ Mn)
Chapter 7 Global Active Pharmaceutical Ingredients Market, by Therapeutic Application
7.1 Market Overview, by Therapeutic Application
7.1.1 Global Active Pharmaceutical Ingredients Market, by Therapeutic Application, 2016-2026 (US$ Mn)
7.1.2 Incremental Opportunity, by Therapeutic Application, From 2018-2026
7.2 Cardiovascular diseases
7.2.1 Global Active Pharmaceutical Ingredients Market, by Cardiovascular diseases, 2016-2026, (US$ Mn)
7.3 Oncology
7.3.1 Global Active Pharmaceutical Ingredients Market, by Oncology, 2016-2026, (US$ Mn)
7.4 Respiratory diseases
7.4.1 Global Active Pharmaceutical Ingredients Market, by Respiratory diseases, 2016-2026, (US$ Mn)
7.5 CNS & Neurology
7.5.1 Global Active Pharmaceutical Ingredients Market, by CNS & Neurology, 2016-2026, (US$ Mn)
7.6 Orthopaedic
7.6.1 Global Active Pharmaceutical Ingredients Market, by Orthopaedic, 2016-2026, (US$ Mn)
7.7 Other therapeutic applications
7.7.1 Global Active Pharmaceutical Ingredients Market, by Other therapeutic applications, 2016-2026, (US$ Mn)
Chapter 8 Global Active Pharmaceutical Ingredients Market, by Region
8.1 Market Overview, by Region
8.1.1 Global Active Pharmaceutical Ingredients Market, by Region, 2016-2026, (US$ Mn)
8.2 Attractive Investment Opportunity, by Region, 2018
8.3 North America Active Pharmaceutical Ingredients Market
8.3.1 North America Active Pharmaceutical Ingredients Market, by Type, 2016-2026 (US$ Mn)
8.3.2 North America Active Pharmaceutical Ingredients Market, by Type of Synthesis, 2016-2026 (US$ Mn)
8.3.3 North America Active Pharmaceutical Ingredients Market, by Type of Manufacturer, 2016-2026 (US$ Mn)
8.3.4 North America Active Pharmaceutical Ingredients Market, by Therapeutic Application, 2016-2026 (US$ Mn)
8.3.5 United States Country Profile
8.3.5.1 United States Active Pharmaceutical Ingredients Market, 2016-2026 (US$ Mn)
8.3.6 Canada Country Profile
8.3.6.1 Canada Active Pharmaceutical Ingredients Market, 2016-2026 (US$ Mn)
8.4 Europe Active Pharmaceutical Ingredients Market
8.4.1 Europe Active Pharmaceutical Ingredients Market, by Type, 2016-2026 (US$ Mn)
8.4.2 Europe Active Pharmaceutical Ingredients Market, by Type of Synthesis, 2016-2026 (US$ Mn)
8.4.3 Europe Active Pharmaceutical Ingredients Market, by Type of Manufacturer, 2016-2026 (US$ Mn)
8.4.4 Europe Active Pharmaceutical Ingredients Market, by Therapeutic Application, 2016-2026 (US$ Mn)
8.4.5 United Kingdom Country Profile
8.4.5.1 United Kingdom Active Pharmaceutical Ingredients Market, 2016-2026 (US$ Mn)
8.4.6 Germany Country Profile
8.4.6.1 Germany Active Pharmaceutical Ingredients Market, 2016-2026 (US$ Mn)
8.4.7 France Country Profile
8.4.7.1 France Active Pharmaceutical Ingredients Market, 2016-2026 (US$ Mn)
8.4.8 Italy Country Profile
8.4.8.1 Italy Active Pharmaceutical Ingredients Market, 2016-2026 (US$ Mn)
8.4.9 Spain Country Profile
8.4.9.1 Spain Active Pharmaceutical Ingredients Market, 2016-2026 (US$ Mn)
8.4.10 Rest of Europe
8.4.10.1 Rest of Europe Active Pharmaceutical Ingredients Market, 2016-2026 (US$ Mn)
8.5 Asia Pacific Active Pharmaceutical Ingredients Market
8.5.1 Asia-Pacific Active Pharmaceutical Ingredients Market, by Type, 2016-2026 (US$ Mn)
8.5.2 Asia-Pacific Active Pharmaceutical Ingredients Market, by Type of Synthesis, 2016-2026 (US$ Mn)
8.5.3 Asia-Pacific Active Pharmaceutical Ingredients Market, by Type of Manufacturer, 2016-2026 (US$ Mn)
8.5.4 Asia-Pacific Active Pharmaceutical Ingredients Market, by Therapeutic Application, 2016-2026 (US$ Mn)
8.5.5 China Country Profile
8.5.5.1 China Active Pharmaceutical Ingredients Market, 2016-2026 (US$ Mn)
8.5.6 Japan Country Profile
8.5.6.1 Japan Active Pharmaceutical Ingredients Market, 2016-2026 (US$ Mn)
8.5.7 India Country Profile
8.5.7.1 India Active Pharmaceutical Ingredients Market, 2016-2026 (US$ Mn)
8.5.8 South Korea Country Profile
8.5.8.1 South Korea Active Pharmaceutical Ingredients Market, 2016-2026 (US$ Mn)
8.5.9 Rest of Asia Pacific
8.5.9.1 Rest of Asia Pacific Active Pharmaceutical Ingredients Market, 2016-2026 (US$ Mn)
8.6 Rest of the World Active Pharmaceutical Ingredients Market
8.6.1 Rest of the World Active Pharmaceutical Ingredients Market, by Type, 2016-2026 (US$ Mn)
8.6.2 Rest of the World Active Pharmaceutical Ingredients Market, by Type of Synthesis, 2016-2026 (US$ Mn)
8.6.3 Rest of the World Active Pharmaceutical Ingredients Market, by Type of Manufacturer, 2016-2026 (US$ Mn)
8.6.4 Rest of the World Active Pharmaceutical Ingredients Market, by Therapeutic Application, 2016-2026 (US$ Mn)
8.6.5 Latin America
8.6.5.1 Latin America Active Pharmaceutical Ingredients Market, 2016-2026 (US$ Mn)
8.6.6 Middle East & Africa
8.6.6.1 Middle East & Africa Active Pharmaceutical Ingredients Market, 2016-2026 (US$ Mn)
Chapter 9 Competitive Intelligence
9.1 Market Players Present in Market Life Cycle
9.2 Top 5 Players Comparison
9.3 Market Positioning of Key Players, 2018
9.4 Market Players Mapping
9.4.1 By Type
9.4.2 By Therapeutic Application
9.4.3 By Type of Synthesis
9.4.4 By Region
9.5 Strategies Adopted by Key Market Players
9.6 Recent Developments in the Market
9.6.1 Mergers & Acquisitions, Partnership, New Product Developments
9.7 Operational Efficiency Comparison by Key Players
Chapter 10 Company Profiles
10.1 AbbVie Inc.
10.1.1 AbbVie Inc. Overview
10.1.2 Key Stakeholders/Person in AbbVie Inc.
10.1.3 AbbVie Inc. Products Portfolio
10.1.4 AbbVie Inc. Financial Overview
10.1.5 AbbVie Inc. News/Recent Developments
10.2 AstraZeneca Plc
10.2.1 AstraZeneca Plc Overview
10.2.2 Key Stakeholders/Person in AstraZeneca Plc
10.2.3 AstraZeneca Plc Products Portfolio
10.2.4 AstraZeneca Plc Financial Overview
10.2.5 AstraZeneca Plc News/Recent Developments
10.3 Boehringer Ingelheim
10.3.1 Boehringer Ingelheim Overview
10.3.2 Key Stakeholders/Person in Boehringer Ingelheim
10.3.3 Boehringer Ingelheim Products Portfolio
10.3.4 Boehringer Ingelheim Financial Overview
10.3.5 Boehringer Ingelheim News/Recent Developments
10.4 Bristol-Myers Squibb
10.4.1 Bristol-Myers Squibb Overview
10.4.2 Key Stakeholders/Person in Bristol-Myers Squibb
10.4.3 Bristol-Myers Squibb Products Portfolio
10.4.4 Bristol-Myers Squibb Financial Overview
10.4.5 Bristol-Myers Squibb News/Recent Developments
10.5 Eli Lilly and Company
10.5.1 Eli Lilly and Company Overview
10.5.2 Key Stakeholders/Person in Eli Lilly and Company
10.5.3 Eli Lilly and Company Products Portfolio
10.5.4 Eli Lilly and Company Financial Overview
10.5.5 Eli Lilly and Company News/Recent Developments
10.6 GlaxoSmithKline Plc.
10.6.1 GlaxoSmithKline Plc. Overview
10.6.2 Key Stakeholders/Person in GlaxoSmithKline Plc.
10.6.3 GlaxoSmithKline Plc. Products Portfolio
10.6.4 GlaxoSmithKline Plc. Financial Overview
10.6.5 GlaxoSmithKline Plc. News/Recent Developments
10.7 Merck & Co. Inc.
10.7.1 Merck & Co. Inc. Overview
10.7.2 Key Stakeholders/Person in Merck & Co. Inc.
10.7.3 Merck & Co. Inc. Products Portfolio
10.7.4 Merck & Co. Inc. Financial Overview
10.7.5 Merck & Co. Inc. News/Recent Developments
10.8 Novartis AG
10.8.1 Novartis AG Overview
10.8.2 Key Stakeholders/Person in Novartis AG
10.8.3 Novartis AG Products Portfolio
10.8.4 Novartis AG Financial Overview
10.8.5 Novartis AG News/Recent Developments
10.9 Pfizer Inc.
10.9.1 Pfizer Inc. Overview
10.9.2 Key Stakeholders/Person in Pfizer Inc.
10.9.3 Pfizer Inc. Products Portfolio
10.9.4 Pfizer Inc. Financial Overview
10.9.5 Pfizer Inc. News/Recent Developments
10.10 Teva Pharmaceuticals
10.10.1 Teva Pharmaceuticals Overview
10.10.2 Key Stakeholders/Person in Teva Pharmaceuticals
10.10.3 Teva Pharmaceuticals Products Portfolio
10.10.4 Teva Pharmaceuticals Financial Overview
10.10.5 Teva Pharmaceuticals News/Recent Developments
TABLE 1 Market Snapshot: Global Active Pharmaceutical Ingredients Market Value
TABLE 2 Global Active Pharmaceutical Ingredients Market, by Type, 2016-2026 (US$ Mn)
TABLE 3 Global Active Pharmaceutical Ingredients Market, by Type of Synthesis, 2016-2026 (US$ Mn)
TABLE 4 Global Active Pharmaceutical Ingredients Market, by Type of Manufacturer, 2016-2026 (US$ Mn)
TABLE 5 Global Active Pharmaceutical Ingredients Market, by Therapeutic Application, 2016-2026 (US$ Mn)
TABLE 6 Global Active Pharmaceutical Ingredients Market, by Region, 2016-2026 (US$ Mn)
TABLE 7 North America Active Pharmaceutical Ingredients Market, by Type, 2016-2026 (US$ Mn)
TABLE 8 North America Active Pharmaceutical Ingredients Market, by Type of Synthesis, 2016-2026 (US$ Mn)
TABLE 9 North America Active Pharmaceutical Ingredients Market, by Type of Manufacturer, 2016-2026 (US$ Mn)
TABLE 10 North America Active Pharmaceutical Ingredients Market, by Therapeutic Application, 2016-2026 (US$ Mn)
TABLE 11 Europe Active Pharmaceutical Ingredients Market, by Type, 2016-2026 (US$ Mn)
TABLE 12 Europe Active Pharmaceutical Ingredients Market, by Type of Synthesis, 2016-2026 (US$ Mn)
TABLE 13 Europe Active Pharmaceutical Ingredients Market, by Type of Manufacturer, 2016-2026 (US$ Mn)
TABLE 14 Europe Active Pharmaceutical Ingredients Market, by Therapeutic Application, 2016-2026 (US$ Mn)
TABLE 15 Asia-Pacific Active Pharmaceutical Ingredients Market, by Type, 2016-2026 (US$ Mn)
TABLE 16 Asia-Pacific Active Pharmaceutical Ingredients Market, by Type of Synthesis, 2016-2026 (US$ Mn)
TABLE 17 Asia-Pacific Active Pharmaceutical Ingredients Market, by Type of Manufacturer, 2016-2026 (US$ Mn)
TABLE 18 Asia-Pacific Active Pharmaceutical Ingredients Market, by Therapeutic Application, 2016-2026 (US$ Mn)
TABLE 19 Rest of the World Active Pharmaceutical Ingredients Market, by Type, 2016-2026 (US$ Mn)
TABLE 20 Rest of the World Active Pharmaceutical Ingredients Market, by Type of Synthesis, 2016-2026 (US$ Mn)
TABLE 21 Rest of the World Active Pharmaceutical Ingredients Market, by Type of Manufacturer, 2016-2026 (US$ Mn)
TABLE 22 Rest of the World Active Pharmaceutical Ingredients Market, by Therapeutic Application, 2016-2026 (US$ Mn)
TABLE 23 Top 5 Players Comparison
TABLE 24 Market Players Mapping – By Type
TABLE 25 Market Players Mapping – By Therapeutic Application
TABLE 26 Market Players Mapping – By Type of Synthesis
TABLE 27 Top Players Market Mapping – By Region
TABLE 28 Strategies Adopted by Key Market Players
TABLE 29 Mergers & Acquisitions, Partnership, New Product Developments
TABLE 30 AbbVie Inc. Overview
TABLE 31 Key Stakeholders/Person in AbbVie Inc.
TABLE 32 AbbVie Inc. Product Portfolio
TABLE 33 AbbVie Inc. News/Recent Developments
TABLE 34 AstraZeneca Plc Overview
TABLE 35 Key Stakeholders/Person in AstraZeneca Plc
TABLE 36 AstraZeneca Plc Product Portfolio
TABLE 37 AstraZeneca Plc News/Recent Developments
TABLE 38 Boehringer Ingelheim Overview
TABLE 39 Key Stakeholders/Person in Boehringer Ingelheim
TABLE 40 Boehringer Ingelheim Product Portfolio
TABLE 41 Boehringer Ingelheim News/Recent Developments
TABLE 42 Bristol-Myers Squibb Overview
TABLE 43 Key Stakeholders/Person in Bristol-Myers Squibb
TABLE 44 Bristol-Myers Squibb Product Portfolio
TABLE 45 Bristol-Myers Squibb News/Recent Developments
TABLE 46 Eli Lilly and Company Overview
TABLE 47 Key Stakeholders/Person in Eli Lilly and Company
TABLE 48 Eli Lilly and Company Product Portfolio
TABLE 49 Eli Lilly and Company News/Recent Developments
TABLE 50 GlaxoSmithKline Plc. Overview
TABLE 51 Key Stakeholders/Person in GlaxoSmithKline Plc.
TABLE 52 GlaxoSmithKline Plc. Product Portfolio
TABLE 53 GlaxoSmithKline Plc. News/Recent Developments
TABLE 54 Merck & Co. Inc. Overview
TABLE 55 Key Stakeholders/Person in Merck & Co. Inc.
TABLE 56 Merck & Co. Inc. Product Portfolio
TABLE 57 Merck & Co. Inc. News/Recent Developments
TABLE 58 Novartis AG Overview
TABLE 59 Key Stakeholders/Person in Novartis AG
TABLE 60 Novartis AG Product Portfolio
TABLE 61 Novartis AG News/Recent Developments
TABLE 62 Pfizer Inc. Overview
TABLE 63 Key Stakeholders/Person in Pfizer Inc.
TABLE 64 Pfizer Inc. Product Portfolio
TABLE 65 Pfizer Inc. News/Recent Developments
TABLE 66 Teva Pharmaceuticals Overview
TABLE 67 Key Stakeholders/Person in Teva Pharmaceuticals
TABLE 68 Teva Pharmaceuticals Product Portfolio
TABLE 69 Teva Pharmaceuticals News/Recent Developments
